Hikma Pharmaceuticals Plc (LON: HIK) has recently received a number of price target changes and ratings updates:

  • 8/29/2017 – Hikma Pharmaceuticals Plc was downgraded by analysts at Stifel Nicolaus to a “hold” rating. They now have a GBX 1,320 ($17.07) price target on the stock, down previously from GBX 2,300 ($29.75).
  • 8/25/2017 – Hikma Pharmaceuticals Plc had its price target lowered by analysts at Barclays PLC from GBX 2,200 ($28.45) to GBX 1,500 ($19.40). They now have an “overweight” rating on the stock.
  • 8/24/2017 – Hikma Pharmaceuticals Plc had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a GBX 1,350 ($17.46) price target on the stock.
  • 8/22/2017 – Hikma Pharmaceuticals Plc was downgraded by analysts at Goldman Sachs Group, Inc. (The) to a “neutral” rating. They now have a GBX 1,310 ($16.94) price target on the stock, down previously from GBX 2,600 ($33.63).
  • 8/21/2017 – Hikma Pharmaceuticals Plc had its price target lowered by analysts at Jefferies Group LLC from GBX 1,390 ($17.98) to GBX 1,045 ($13.52). They now have a “hold” rating on the stock.
  • 8/21/2017 – Hikma Pharmaceuticals Plc was downgraded by analysts at Morgan Stanley to an “equal weight” rating. They now have a GBX 1,350 ($17.46) price target on the stock, down previously from GBX 1,600 ($20.69).
  • 8/17/2017 – Hikma Pharmaceuticals Plc had its “hold” rating reaffirmed by analysts at Peel Hunt. They now have a GBX 2,150 ($27.81) price target on the stock.
  • 8/17/2017 – Hikma Pharmaceuticals Plc had its “add” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 1,560 ($20.18) price target on the stock.
  • 8/11/2017 – Hikma Pharmaceuticals Plc had its “add” rating reaffirmed by analysts at Numis Securities Ltd. They now have a GBX 1,560 ($20.18) price target on the stock.
  • 8/2/2017 – Hikma Pharmaceuticals Plc was downgraded by analysts at Morgan Stanley to an “equal weight” rating. They now have a GBX 1,600 ($20.69) price target on the stock, down previously from GBX 2,050 ($26.51).
  • 7/4/2017 – Hikma Pharmaceuticals Plc had its “reduce” rating reaffirmed by analysts at HSBC Holdings plc. They now have a GBX 1,800 ($23.28) price target on the stock.
  • 7/3/2017 – Hikma Pharmaceuticals Plc had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a GBX 2,200 ($28.45) price target on the stock.

Hikma Pharmaceuticals Plc (LON HIK) traded down 0.62% during midday trading on Tuesday, reaching GBX 1280.00. 566,065 shares of the company’s stock traded hands. The company’s 50-day moving average price is GBX 1,345.28 and its 200-day moving average price is GBX 1,733.12. Hikma Pharmaceuticals Plc has a 52-week low of GBX 1,101.00 and a 52-week high of GBX 2,346.00. The stock’s market cap is GBX 3.07 billion.

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.